News

Pfizer Licenses Autoimmune Disease Programs From Starna In Deal Worth Upto $2.63 Bln

NASDAQ

(RTTNews) - Drugmaker Pfizer Inc. (PFE) announced on Wednesday that it has entered into an exclusive licensing agreement with biotechnology company Starna Therapeutics for three preclinical in vivo CAR-T programs targeting autoimmune diseases.

Read the full Veytics brief

We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.